Daily Respiratory Research Analysis
Analyzed 257 papers and selected 3 impactful papers.
Summary
A multicenter randomized trial follow-up links ultra-low tidal volume ventilation in COVID-19 ARDS to small but significant 1-year cognitive decline, likely related to higher PaCO2. Two mechanistic studies illuminate fibrosis and COPD remodeling: vitronectin in 3D matrices programs profibrotic macrophages relevant to idiopathic pulmonary fibrosis, and epithelial SLC3A2-driven branched-chain amino acid influx promotes airway inflammation/remodeling via PFN1 acetylation.
Research Themes
- Ventilator strategy and long-term neurocognitive outcomes in ARDS
- Macrophage-ECM crosstalk driving pulmonary fibrosis
- Epithelial metabolic reprogramming in COPD airway remodeling
Selected Articles
1. Vitronectin metabolically programs profibrotic macrophages in 3D cultures and idiopathic pulmonary fibrosis.
Using a 3D macrophage culture that recapitulates biophysical cues, the authors demonstrate that vitronectin programs a previously unrecognized profibrotic macrophage phenotype marked by metabolic rewiring (NAD-associated pathways) and link these features to idiopathic pulmonary fibrosis tissue. The work highlights ECM composition as an instructive regulator of macrophage metabolism and fibrosis.
Impact: This study provides a mechanistic, ECM-directed switch for profibrotic macrophage programming with direct relevance to IPF, using a methodologically innovative 3D system that better mirrors in vivo context.
Clinical Implications: Targeting vitronectin-macrophage interactions or downstream metabolic nodes (e.g., NAD-related pathways) may offer anti-fibrotic strategies in IPF beyond current antifibrotics by reprogramming macrophage states.
Key Findings
- A 3D in vitro macrophage model uncovered a vitronectin-driven profibrotic phenotype not observed in 2D.
- This phenotype exhibits metabolic rewiring involving NAD-associated pathways.
- Findings connect ECM composition to macrophage programming and are linked to IPF tissue features.
Methodological Strengths
- Physiologically relevant 3D culture capturing biophysical microenvironment
- Integration of ECM cues with macrophage phenotyping and metabolic readouts
Limitations
- Abstract truncation limits detailed understanding of specific metabolic markers and validation cohorts
- Translational efficacy in vivo and therapeutic modulation remain to be demonstrated
Future Directions: Elucidate precise NAD-linked metabolic enzymes and signaling nodes, validate in IPF patient samples and in vivo models, and assess pharmacologic inhibition of vitronectin–macrophage axes.
Macrophages are key drivers of inflammatory and fibrotic diseases, and their activation is shaped by interactions in their tissue microenvironment. However, dissecting the processes that drive immunopathology has proved challenging, as traditional two-dimensional (2D) culture methods fail to capture the complex molecular environment that macrophages inhabit in vivo. To address this, we generated a 3D in vitro model to better mimic the in vivo biophysical microenvironment. We show that the extracellular matrix protein vitronectin promotes a previously unknown profibrotic macrophage phenotype in 3D that is characterized by increased expression of the nicotinamide adenine dinucleotide (NAD
2. Impact of ultra-low tidal volume ventilation on 1-year functional outcome in COVID-19 ARDS patients. A long-term follow-up analysis of a randomized controlled trial.
In this multicenter RCT follow-up (n=215), ultra-low tidal volume did not reduce 1-year mortality compared with conventional low tidal volume in COVID-19 ARDS, but was associated with a small yet statistically significant decline in cognitive status at 365 days, plausibly linked to higher PaCO2 exposure.
Impact: This trial directly informs ventilator strategy trade-offs by linking ULTV to long-term neurocognitive outcomes, elevating cognition as a critical endpoint in ARDS care.
Clinical Implications: In severe ARDS, ULTV may not confer survival benefit and could risk neurocognitive sequelae via hypercapnia; clinicians should balance lung-protective aims with permissive hypercapnia thresholds and consider cognitive follow-up.
Key Findings
- In 215 randomized patients, 1-year mortality did not differ between ULTV and LTV arms.
- ULTV was associated with a small but significant decline in cognitive status at day 365.
- Findings point to higher PaCO2 exposure under ULTV as a plausible contributor to cognitive effects.
Methodological Strengths
- Multicenter randomized controlled design with prespecified registration
- One-year functional outcome assessment beyond in-hospital endpoints
Limitations
- Open-label design may introduce performance bias
- Missing outcome data in a subset of survivors; COVID-era practice patterns may limit generalizability
Future Directions: Define safe PaCO2 targets balancing lung protection and neurocognitive outcomes; incorporate cognitive endpoints into ventilator strategy trials and test interventions mitigating hypercapnia-related neurotoxicity.
BACKGROUND: Ultra-low tidal volume ventilation (ULTV) aims to minimize ventilator-induced lung injury in acute respiratory distress syndrome (ARDS), but is associated with an increase in arterial carbon dioxide (PaCO METHODS: VT4COVID was an open-label multicenter randomized controlled superiority trial performed in ten French intensive care units. Eligible patients were COVID-19 ARDS patients with arterial oxygen pressure (PaO RESULTS: Two hundred and fifteen patients were randomized to ULTV (n = 106) or LTV (n = 109) between April,2020 and April,2021. Seven patients were lost to follow-up and 34 surviving patients had missing data for at least one score. Mortality at day-365 was not significantly different between ULTV and LTV arms (47/102 [46%] vs. 44/106 [42%], hazard ratio 1.19 (95% confidence interval (CI CONCLUSIONS: ULTV is associated with a small but significant decrease in cognitive status at day-365 possibly related to exposure to higher PaCO TRIAL REGISTRATION: The trial was prospectively registered with ClinicalTrials.gov (NCT04349618) on April 16, 2020.
3. SLC3A2-mediated BCAAs transport promotes airway inflammation and remodeling in chronic obstructive pulmonary disease via acetylation of PFN1.
COPD airway epithelium upregulates SLC3A2 and displays BCAA imbalance. Epithelial Slc3a2 knockout attenuated cigarette smoke–induced airway inflammation and remodeling. Mechanistically, SLC3A2-driven BCAA influx increased acetyl-CoA and PFN1 acetylation, activating PI3K/AKT; HECTD4 downregulation promoted SLC3A2 upregulation.
Impact: Defines a metabolic-epithelial axis (SLC3A2–BCAA–PFN1 acetylation) causally linking cigarette smoke to airway remodeling, revealing druggable nodes in COPD.
Clinical Implications: Inhibiting SLC3A2 or downstream PFN1 acetylation/PI3K-AKT signaling could complement anti-inflammatory therapy to limit airway remodeling in COPD, especially in smokers.
Key Findings
- COPD patients and smoke-exposed mice showed BCAA imbalance with epithelial SLC3A2 upregulation.
- Airway epithelial Slc3a2 knockout mitigated smoke-induced inflammation and remodeling in vivo.
- SLC3A2-mediated BCAA influx increased acetyl-CoA and PFN1 acetylation, activating PI3K/AKT; HECTD4 downregulation drove SLC3A2 upregulation.
Methodological Strengths
- Convergent evidence across human samples, mouse genetics, and epithelial cell models
- Mechanistic depth linking metabolite flux to post-translational modification and signaling
Limitations
- Clinical cohort size and external validation are not detailed in the abstract
- Therapeutic inhibition data are preclinical; safety/efficacy in humans unknown
Future Directions: Validate SLC3A2 and PFN1 acetylation as biomarkers/targets in longitudinal COPD cohorts; develop selective inhibitors or biologics and test in smoke-exposed large-animal models.
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) remains a leading cause of global burden, characterized by persistent airway inflammation and remodeling. Our previous study identified branched-chain amino acids (BCAAs) imbalance in patients with COPD, suggesting a potential contribution of metabolic reprogramming to the disease process. Solute carrier family 3 member 2 (SLC3A2), a key transporter for BCAAs uptake, plays a crucial role in amino acid homeostasis, yet its function in COPD pathogenesis remains unknown. This gap highlights the need to investigate whether SLC3A2-mediated BCAAs transport contributes to COPD. OBJECTIVES: Building on our prior findings, this study aims to investigate the role of SLC3A2 in COPD-associated airway inflammation and remodeling, along with its regulatory mechanisms. METHODS: SLC3A2 expression and BCAAs levels were quantified in clinical specimens and cigarette smoke (CS)-exposed animal and cellular models. The functional impact of SLC3A2 was assessed using lung function tests and histopathology in mice with airway epithelium-specific Slc3a2 knockout. In human bronchial epithelial (HBE) cells, SLC3A2 was modulated via knockdown or overexpression to elucidate its role in inflammation and remodeling. Immunoprecipitation assays were employed to identify regulators of SLC3A2 expression. RESULTS: BCAAs disturbance and SLC3A2 upregulation were identified in COPD participants and CS-exposed mice, especially in airway epithelial cells. Airway epithelium-specific Slc3a2 knockout in mice alleviated BCAAs imbalance, airway inflammation and remodeling caused by CS. Mechanistically, SLC3A2-mediated BCAAs influx into epithelial cells enhanced acetyl coenzyme A production and profilin1 (PFN1) acetylation, activating the PI3K/AKT signaling axis and exacerbating inflammatory and remodeling responses. Notably, SLC3A2 upregulation was driven by CS-induced downregulation of HECT domain E3 ubiquitin protein ligase 4 (HECTD4). CONCLUSION: This study elucidates the effects of SLC3A2-regulated BCAAs transport on airway inflammation and remodeling in COPD. Targeting SLC3A2 is a potential therapeutic approach for BCAAs imbalance and subsequent progression of COPD.